NEWS & INDUSTRY UPDATES
Canada’s First Psychedelic Training Program for Mental Health Professionals Concludes and is Deemed a Huge Success
Innovative training program provides therapists across the country with access to leading-edge training on psychedelic medicine and assisted therapy with Continuing Education Credits
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada’s Section 56(1) Exemption.
Psilocybin with Psychological Support for Treatment-Resistant Depression: An Open-Label Feasibility Study
Study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression.
Psilocybin Produces Substantial & Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer
Study finds that high-dose psilocybin produced large decreases in measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
ATMA Journey Centers Announces International Expansion to Costa Rica, Providing Clients A Range Of Psychedelic Treatments Including Ayahuasca
Azul Journey Center will be guided by deeply experienced plant medicine elders of ancient cultural lineage who will assist in building the program’s vision, operations and protocols
MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
The completed equity investment strengthens ties between MINDCURE and ATMA.